medsci-skills 4.1.0

package/skills/find-journal/references/journal_profiles/JAMA_Network_Open.md

@@ -0,0 +1,30 @@
+# JAMA Network Open
+
+## Identity
+- **Abbreviation:** JAMA Netw Open
+- **Publisher:** American Medical Association (AMA)
+- **ISSN:** 2574-3805
+- **Homepage:** https://jamanetwork.com/journals/jamanetworkopen
+- **Author guidelines:** https://jamanetwork.com/journals/jamanetworkopen/pages/instructions-for-authors
+
+## Scope
+JAMA Network Open is a fully open access, multidisciplinary journal publishing original research across all areas of medicine, including clinical care, innovation in health care, and global health. It publishes studies that advance medical knowledge, improve clinical practice, or inform health policy, accepting a broader range of study designs and sample sizes than JAMA.
+
+## Scope Keywords
+clinical research, observational studies, randomized trials, health outcomes, health services research, global health, public health, epidemiology, medical AI, diagnostic accuracy, quality improvement, patient safety, disparities, digital health, cohort study
+
+## Article Types Accepted
+- Original Investigation
+- Research Letter
+- Invited Commentary
+- Systematic Review and Meta-Analysis
+- Diagnostic/Prognostic Study
+- US Preventive Services Task Force
+
+## Classification
+- **Tier:** Q1
+- **Open Access:** Full OA (APC ~$3,500)
+- **Field:** General medicine (multidisciplinary)
+
+## Special Notes
+JAMA Network Open is the most accessible high-impact general medical journal for original research. It accepts studies across all specialties including AI/radiology with clinical endpoints, diagnostic accuracy studies, and meta-analyses. Shares JAMA's structured abstract (7-heading) and Key Points box requirements. APC waiver available for LMIC authors. Acceptance rate ~15-20%. AI policy: language editing only, Methods + cover letter disclosure required per JAMA Network policy.

package/skills/find-journal/references/journal_profiles/JCSM.md

@@ -0,0 +1,39 @@
+# Journal of Cachexia, Sarcopenia and Muscle
+
+## Identity
+- **Abbreviation:** J Cachexia Sarcopenia Muscle (JCSM)
+- **Publisher:** Wiley
+- **ISSN:** [TODO: verify at JCSM journal page]
+- **Homepage:** https://onlinelibrary.wiley.com/journal/13989440
+- **Author guidelines:** https://onlinelibrary.wiley.com/page/journal/13989440/homepage/forauthors.html
+- **Submission portal:** https://authors.wiley.com/journal/JCSM/
+
+## Scope
+The Journal of Cachexia, Sarcopenia and Muscle is the dedicated international journal for cachexia, sarcopenia, body composition, and skeletal-muscle and adipose-tissue physiology/pathophysiology across the lifespan and across chronic diseases (cancer, heart failure, lung disease, cirrhosis, kidney failure, rheumatoid arthritis, sepsis, AIDS). The journal serves researchers and clinicians studying muscle wasting, lipolysis, sarcopenic obesity, ageing-related body composition changes, and prognostic/diagnostic biomarkers for these conditions.
+
+## Scope Keywords
+cachexia, sarcopenia, sarcopenic obesity, body composition, skeletal muscle, muscle wasting, adipose tissue, lipolysis, ageing, frailty, chronic disease, cancer cachexia, heart failure cachexia, COPD muscle wasting, cirrhosis sarcopenia, kidney failure cachexia, prognostic markers, body composition imaging, bioelectrical impedance, DXA, CT body composition, muscle biomarkers
+
+## Article Types Accepted
+- Original Article (4,500 words, abstract 400 structured data-rich, refs 40, ≤8 figures/tables with max 6 sub-sections per figure)
+- Review (6,000 words, abstract 400 unstructured data-rich, refs 120)
+- Editorial (invited only; 1,500 words; Facts & Numbers series allows abstract up to 400 words)
+- Research/Scientific Letter (1,200 words, 1 figure/table, 10 refs)
+- Short Report (1,500 words, ≤2 figures/tables, 10 refs)
+- Meeting Report (1,500 words, 20 refs)
+- Reply / Letter to the Editor (1,200 words)
+
+## Classification
+- **Tier:** Q1 (specialty journal — dedicated to cachexia/sarcopenia/body composition)
+- **Open Access:** Gold OA, APC required on acceptance (waivers/discounts may apply)
+- **Field:** Cachexia / Sarcopenia / Body Composition / Skeletal Muscle / Adipose Tissue
+
+## Special Notes
+JCSM is the dedicated international journal for cachexia, sarcopenia, and body composition research, published by Wiley under Gold Open Access (APC required on acceptance). **Single-blind peer review.** Continuous publication model (articles publish to online issue when ready; no issue pagination delay). Title cap ≤17 words / 120 characters. **Abstract must be data-rich (≤400 words, structured: Background/Methods/Results/Conclusions) with actual numbers, effect sizes, hazard ratios, 95% CIs, and p-values — "descriptive results abstracts are not acceptable."** Original Article body ≤4,500 words; 40 references in main + unlimited supplement (S1, S2, ...). **Only ONE corresponding author per submission**; multiple co-first or equal-contribution requests must be declared in cover letter. **For survival/prognostic studies, JCSM enforces strict reporting**: 1-year mortality rate with 95% CI (plus 5-year and/or 3-month as appropriate) in both abstract AND methods/results; Kaplan-Meier plots with "patients at risk" annotation at baseline + follow-up intervals; novel prognostic markers expected from cohorts with ≥60–100 events, novel prognostic scores ≥150–200 events. Validation in second cohort strongly recommended. Reference style flexible (since August 2024) but must be consistent and complete (author, year, journal/book, article title, volume, pages, DOI optional). Preprints permitted (declare server + accession/DOI in cover letter). AI policy: [TODO: verify at journal AI policy page] — Wiley publisher-wide policy generally requires disclosure of AI tools and bars AI as author.
+
+
+---
+
+## Verification
+- **Source:** https://onlinelibrary.wiley.com/page/journal/13989440/homepage/forauthors.html
+- **Date:** 2026-05-21

package/skills/find-journal/references/journal_profiles/JKMS.md

@@ -0,0 +1,32 @@
+# Journal of Korean Medical Science
+
+## Identity
+- **Abbreviation:** J Korean Med Sci
+- **Publisher:** Korean Academy of Medical Sciences (KAMS)
+- **ISSN:** 1011-8934 (print) / 1598-6357 (electronic)
+- **Homepage:** https://jkms.org
+- **Author guidelines:** https://jkms.org (Author Information section)
+- **Submission portal:** https://submit.jkms.org
+
+## Scope
+JKMS publishes original research, reviews, case reports, and editorials across all medical specialties — clinical, basic-science, public-health, and epidemiology. The journal is the leading generalist English-language medical journal published by the Korean Academy of Medical Sciences with broad receptivity to Korean and East Asian population studies, single-institution observational research, and cross-disciplinary work with clear clinical implications.
+
+## Scope Keywords
+general medicine, Korean population, East Asian medicine, clinical epidemiology, public health, observational cohort, retrospective cohort, single-institution study, IRB-approved retrospective study, cross-disciplinary medicine, MD-MD-research
+
+## Article Types Accepted
+- Original Article (3,000 words, 6 figures)
+- Review Article (invited, ≤6 figures)
+- Brief Communication (1,500 words, 3 figures)
+- Case Report (1,500 words, 4 figures)
+- Case Conference for CME (2,500 words, 6 figures)
+- Editorial / Opinion / Guideline (600–1,500 words)
+- Correspondence (600 words, 1 figure)
+
+## Classification
+- **Tier:** Q1 (generalist medical journal)
+- **Open Access:** Full OA, indexed in PubMed/MEDLINE, SCIE, Scopus
+- **Field:** General Medicine
+
+## Special Notes
+JKMS is the flagship English-language generalist medical journal published by the Korean Academy of Medical Sciences, weekly online-only. References use Vancouver format with EndNote `jkms.ens` provided. Strict 3,000-word limit for original articles (Methods + Results + Discussion + Conclusion); abstract structured to 350 words (Background-Methods-Results-Conclusion). Submission requires title-page docx, main-body docx, tables/figures separate uploads, cover letter (addressed to EIC), per-author ICMJE COI, CRediT contributor declarations, and Data Availability Statement. APC charged on acceptance. AI policy follows ICMJE: disclose AI use in cover letter; AI cannot be listed as author. Typical review timeline ~8 weeks. Particularly receptive to Korean cohort studies with broad medical relevance and to single-institution observational work with clear clinical implications.

package/skills/find-journal/references/journal_profiles/JMIR.md

@@ -0,0 +1,29 @@
+# Journal of Medical Internet Research
+
+## Identity
+- **Abbreviation:** J Med Internet Res
+- **Publisher:** JMIR Publications
+- **ISSN:** 1438-8871 (online only)
+- **Homepage:** https://www.jmir.org/
+- **Author guidelines:** https://www.jmir.org/author-instructions
+
+## Scope
+Flagship journal of JMIR Publications covering digital health, health informatics, and emerging technologies applied to healthcare delivery. ML papers accepted only with direct clinical impact and independent validation. Pure clinical informatics without patient/consumer empowerment angle is routed to sister journals.
+
+## Scope Keywords
+digital health, mHealth, telemedicine, health informatics, eHealth, wearable devices, patient engagement, clinical decision support, health apps, internet intervention, remote monitoring, online health communities, digital therapeutics, artificial intelligence in health, consumer health informatics, virtual care
+
+## Article Types Accepted
+- Original Paper
+- Digital Health Review
+- Viewpoint/Perspective
+- Research Letter
+- Policy Paper
+
+## Classification
+- **Tier:** Q1
+- **Open Access:** Full OA (Gold)
+- **Field:** Digital health / Health informatics
+
+## Special Notes
+Ranked #1 in Medical Informatics by Google Scholar; highly selective with cascading peer review to JMIR sister journals. Fast-track option available (4-week turnaround). No bare URLs in body text — all must be cited as references. AI policy: follows ICMJE — disclose AI use in Methods.

package/skills/find-journal/references/journal_profiles/JMIR_Medical_Education.md

@@ -0,0 +1,29 @@
+# JMIR Medical Education
+
+## Identity
+- **Abbreviation:** JMIR Med Educ
+- **Publisher:** JMIR Publications
+- **ISSN:** 2369-3762 (online only)
+- **Homepage:** https://mededu.jmir.org/
+- **Author guidelines:** https://mededu.jmir.org/author-instructions
+
+## Scope
+Covers digital technology in medical and health professions education, including e-learning, simulation, AI-assisted teaching, virtual reality training, and online assessment. Bridges health informatics and education research with emphasis on technology-mediated learning innovations.
+
+## Scope Keywords
+medical education technology, e-learning, simulation-based education, virtual reality training, artificial intelligence in education, online assessment, gamification, digital literacy, learning analytics, mobile learning, telemedicine education, virtual patients, augmented reality, large language models in education, competency-based digital education
+
+## Article Types Accepted
+- Original Paper
+- Review
+- Viewpoint
+- Policy Paper
+- Students' Corner
+
+## Classification
+- **Tier:** Q1
+- **Open Access:** Full OA (CC BY 4.0)
+- **Field:** Medical education technology
+
+## Special Notes
+High-impact (IF ~12.6) JMIR sister journal focused on technology-enhanced medical education. Cascading peer review from JMIR flagship; single-blind with named reviewers published alongside accepted articles. Fast-track option (20 working days). AI policy: generative AI use must be disclosed per JMIR AI policy.

package/skills/find-journal/references/journal_profiles/JNIS.md

@@ -0,0 +1,35 @@
+# Journal of NeuroInterventional Surgery
+
+## Identity
+- **Abbreviation:** J NeuroIntervent Surg (JNIS)
+- **Publisher:** BMJ Publishing Group / Society of NeuroInterventional Surgery (SNIS)
+- **ISSN:** 1759-8478 (print) / 1759-8486 (online)
+- **Homepage:** https://jnis.bmj.com
+- **Author guidelines:** https://jnis.bmj.com/pages/authors/
+
+## Scope
+JNIS publishes original research, reviews, and case material on endovascular and surgical neurointervention — acute ischemic stroke thrombectomy, intracranial aneurysm coiling and flow diversion, AVM and dAVF embolization, carotid and intracranial stenting, spine interventions, and emerging neurointerventional devices and techniques. The journal is the official journal of the Society of NeuroInterventional Surgery (SNIS) and partners with several international neurointerventional societies.
+
+## Scope Keywords
+mechanical thrombectomy, intracranial aneurysm, flow diverter, coil embolization, arteriovenous malformation, dural arteriovenous fistula, carotid stenting, acute ischemic stroke intervention, endovascular treatment, neurointerventional device, stroke imaging, clot analysis, angiography, intracranial atherosclerosis
+
+## Article Types Accepted
+- Original Research
+- Review
+- Case Series
+- Brief Report
+- Short Report
+- Case Report (brief format)
+- Technical Note / New Device
+- Socioeconomics
+- Editorial / Commentary
+- Letter to the Editor / e-Letter
+- Video Report
+
+## Classification
+- **Tier:** Q1
+- **Open Access:** Hybrid (optional Gold OA with APC; standard subscription route free to authors)
+- **Field:** Neurointervention / endovascular neurosurgery / interventional neuroradiology
+
+## Special Notes
+Official journal of SNIS. Peer review is double-anonymised — author identities removed from the manuscript file. ORCID iD is mandatory for the submitting author. Original Research requires a structured 250-word abstract and a "Key messages" summary box with three bullets (What is already known / What this study adds / How this study might affect research, practice or policy). Follows BMJ Tier 3 data-sharing policy: a Data Availability Statement is mandatory for all research articles. Reporting guideline adherence is required (STROBE/CONSORT/PRISMA/STARD/ARRIVE as applicable) and the completed checklist must be uploaded. Acceptance rate approximately 18% with a median first decision around 24 days (BMJ metrics, verify at submission). AI policy follows BMJ/ICMJE: generative AI cannot be listed as an author; any substantive use must be disclosed in Methods and/or Acknowledgments; AI-generated or -manipulated images are not permitted.

package/skills/find-journal/references/journal_profiles/JVIR.md

@@ -0,0 +1,31 @@
+# Journal of Vascular and Interventional Radiology
+
+## Identity
+- **Abbreviation:** J Vasc Interv Radiol
+- **Publisher:** Elsevier (SIR — Society of Interventional Radiology)
+- **ISSN:** 1051-0443 / 1535-7732
+- **Homepage:** https://www.jvir.org/
+- **Author guidelines:** https://www.jvir.org/content/authorinfo
+
+## Scope
+JVIR publishes original research, reviews, meta-analyses, and technical reports on vascular and interventional radiology. Coverage spans all IR procedures including embolization, ablation, vascular access, drainage, thrombolysis, and emerging minimally invasive techniques. The journal also covers quality improvement, practice standards, and clinical outcomes research in IR.
+
+## Scope Keywords
+interventional radiology, vascular interventions, embolization, tumor ablation, percutaneous biopsy, drainage, thrombolysis, IVC filter, venous access, TIPS, TACE, Y-90 radioembolization, IR outcomes, complication classification, quality improvement, standards of practice, image-guided therapy
+
+## Article Types Accepted
+- Clinical Investigation
+- Clinical Practice
+- Technical Report
+- Case Report
+- Review Article
+- Systematic Review / Meta-Analysis
+- Letter to the Editor
+
+## Classification
+- **Tier:** Q2
+- **Open Access:** Hybrid (Elsevier OA option)
+- **Field:** Radiology / Interventional radiology
+
+## Special Notes
+JVIR is the official journal of the Society of Interventional Radiology (SIR). SIR complication classification is mandatory for procedure studies. The journal publishes SIR standards of practice documents and quality improvement studies. JVIR has a North American and international readership. For European-focused IR studies or CBCT-guided intervention meta-analyses, consider CVIR as an alternative or companion target.

package/skills/find-journal/references/journal_profiles/Journal_of_Biomedical_Informatics.md

@@ -0,0 +1,29 @@
+# Journal of Biomedical Informatics
+
+## Identity
+- **Abbreviation:** J Biomed Inform, JBI
+- **Publisher:** Elsevier
+- **ISSN:** 1532-0464 / 1532-0480
+- **Homepage:** https://www.sciencedirect.com/journal/journal-of-biomedical-informatics
+- **Author guidelines:** https://www.elsevier.com/journals/journal-of-biomedical-informatics/1532-0464/guide-for-authors
+
+## Scope
+Journal of Biomedical Informatics publishes research on computational and informatics methods applied to biomedical data. Coverage includes clinical informatics, health information systems, electronic health records, clinical NLP, knowledge representation, decision support systems, and data science applied to health data. It bridges computer science and clinical medicine through information technology.
+
+## Scope Keywords
+biomedical informatics, clinical informatics, electronic health records, clinical decision support, natural language processing, health data science, knowledge representation, ontology, phenotyping, clinical NLP, EHR, prediction models, machine learning clinical data, patient outcomes, data integration
+
+## Article Types Accepted
+- Original Research
+- Review Article
+- Methodological Review
+- Short Communication
+- Special Communication
+
+## Classification
+- **Tier:** Q1
+- **Open Access:** Hybrid
+- **Field:** Medical informatics
+
+## Special Notes
+JBI is distinguished from image-focused AI journals by its emphasis on structured clinical data (EHR, claims, lab results) rather than imaging data. It values methodological rigor and clinical applicability. Studies on large language models for clinical NLP, clinical prediction models, and health information exchange are well-suited. The journal requires clear description of data provenance and clinical context.

package/skills/find-journal/references/journal_profiles/Journal_of_Clinical_Endocrinology_and_Metabolism.md

@@ -0,0 +1,40 @@
+# The Journal of Clinical Endocrinology & Metabolism (JCEM)
+
+## Identity
+- **Abbreviation:** J Clin Endocrinol Metab
+- **Publisher:** Oxford University Press (on behalf of the Endocrine Society)
+- **ISSN:** 0021-972X (print) / 1945-7197 (online)
+- **Homepage:** https://academic.oup.com/jcem
+- **Author guidelines:** https://academic.oup.com/jcem/pages/Author_Guidelines
+
+## Scope
+JCEM positions itself as "the world's leading peer-reviewed journal for endocrine clinical research and clinical practice." Article types span original research, reviews, case reports, commentaries, and consensus statements covering endocrinology, metabolism, diabetes, thyroid, bone, reproductive endocrinology, and adrenal/pituitary disease.
+
+## Scope Keywords
+clinical endocrinology, metabolism, diabetes, thyroid, bone disease, reproductive endocrinology, adrenal disease, pituitary disease, metabolic syndrome, insulin resistance, cardio-metabolic, obesity, lipid metabolism, cardiovascular-kidney-metabolic, CKM staging
+
+## Article Types Accepted
+- Clinical Research Article (Original)
+- Approach to the Patient
+- Mini-review
+- Meta-analysis
+- Editorial
+- Commentary
+- Letter to the Editor
+- Report and Recommendation (society/consensus)
+
+## Classification
+- **Tier:** Q1 (Endocrine Society flagship)
+- **Open Access:** Hybrid — page charge model (USD 99–119 per PDF page member/non-member; color figure surcharge USD 235–735); open access option separate via OUP open-access portal
+- **Field:** Clinical endocrinology and metabolism
+
+## Special Notes
+Editor-in-Chief Paul M. Stewart, MD. Original Articles do not have a stated upper word limit (Approach to the Patient 2,000–5,000 words; Mini-reviews 2,000–5,000 words). Required **250-word structured abstract describing purpose, methods, results, and main conclusions in complete sentences without direct text references**. References use **AMA citation style with consecutive numerical ordering** and the guideline states "List all authors for the initial submission" (no first-N-then-et-al truncation at submission stage). AI policy (verbatim): "The use of artificial intelligence (AI) tools must be disclosed during the submission process and also described in the Methods or Acknowledgments sections of the text." Reviewers are explicitly prohibited from uploading any part of a manuscript into LLM tools during review. Submission portal: https://www.editorialmanager.com/jcem/. Choose JCEM when the metabolic-syndrome / insulin-resistance / cardio-metabolic mechanism is the primary scientific contribution and cardiovascular outcomes serve a supporting role (rather than the inverse).
+
+
+---
+
+## Verification
+- **Source:** https://academic.oup.com/jcem/pages/Author_Guidelines
+- **Date (harvested from private profile):** 2026-05-20
+- **Date (promoted to public):** 2026-05-21

package/skills/find-journal/references/journal_profiles/Journal_of_Magnetic_Resonance_Imaging.md

@@ -0,0 +1,30 @@
+# Journal of Magnetic Resonance Imaging
+
+## Identity
+- **Abbreviation:** JMRI, J Magn Reson Imaging
+- **Publisher:** Wiley (International Society for Magnetic Resonance in Medicine)
+- **ISSN:** 1053-1807 / 1522-2586
+- **Homepage:** https://onlinelibrary.wiley.com/journal/15222586
+- **Author guidelines:** https://onlinelibrary.wiley.com/page/journal/15222586/homepage/forauthors.html
+
+## Scope
+JMRI publishes original research on all aspects of magnetic resonance imaging in medicine, including technical development, clinical applications, and translational research. It covers MRI across all body systems and disease categories, with particular strength in musculoskeletal, neuroimaging, abdominal, and cardiac MRI.
+
+## Scope Keywords
+magnetic resonance imaging, MRI, MR technique, diffusion-weighted imaging, perfusion imaging, MR spectroscopy, contrast agents, gadolinium, liver MRI, cardiac MRI, musculoskeletal MRI, neuroimaging, quantitative MRI, radiomics, deep learning MRI
+
+## Article Types Accepted
+- Original Research
+- Technical Note
+- Review Article
+- Case Report (as Brief Report)
+- Letter to the Editor
+- Pictorial Essay
+
+## Classification
+- **Tier:** Q1
+- **Open Access:** Hybrid
+- **Field:** Radiology / MRI
+
+## Special Notes
+JMRI is the official journal of ISMRM and is the premier MRI-focused journal. It strongly favors studies with MRI-specific technical innovation or clinical validation. AI studies focused on MRI data (segmentation, detection, quantification) are welcomed. The journal values reproducibility and encourages sharing of code and data.

package/skills/find-journal/references/journal_profiles/Journal_of_Nuclear_Medicine.md

@@ -0,0 +1,31 @@
+# Journal of Nuclear Medicine
+
+## Identity
+- **Abbreviation:** JNM, J Nucl Med
+- **Publisher:** Society of Nuclear Medicine and Molecular Imaging (SNMMI)
+- **ISSN:** 0161-5505 / 2159-662X
+- **Homepage:** https://jnm.snmjournals.org/
+- **Author guidelines:** https://jnm.snmjournals.org/page/author-instructions
+
+## Scope
+JNM publishes original research in nuclear medicine, molecular imaging, and theranostics. Coverage includes PET, SPECT, radionuclide therapy, radiopharmaceuticals, and hybrid imaging (PET/CT, PET/MRI). The journal emphasizes clinical and translational studies involving radiotracer development, dosimetry, and molecular-targeted diagnostics and therapies.
+
+## Scope Keywords
+nuclear medicine, PET, SPECT, PET/CT, PET/MRI, radionuclide therapy, theranostics, radiopharmaceuticals, FDG, PSMA, molecular imaging, dosimetry, radiotracer, oncology imaging, neuroendocrine tumors
+
+## Article Types Accepted
+- Original Research (Clinical and Basic Science)
+- Brief Communication
+- Review Article
+- State of the Art
+- Case Report (Interesting Image)
+- Letters to the Editor
+- Continuing Education
+
+## Classification
+- **Tier:** Q1
+- **Open Access:** Hybrid (author choice)
+- **Field:** Nuclear medicine / Molecular imaging
+
+## Special Notes
+JNM is the flagship journal of nuclear medicine. It has strong interest in theranostics (PSMA, Lu-177, etc.) and novel radiotracer development. AI applications in nuclear medicine (automated quantification, lesion detection on PET) are increasingly published. The journal has a companion publication, Journal of Nuclear Medicine Technology.

package/skills/find-journal/references/journal_profiles/Journal_of_Stroke.md

@@ -0,0 +1,32 @@
+# Journal of Stroke
+
+## Identity
+- **Abbreviation:** J Stroke
+- **Publisher:** Korean Stroke Society
+- **ISSN:** 2287-6391 (print) / 2287-6405 (online)
+- **Homepage:** http://j-stroke.org
+- **Author guidelines:** https://j-stroke.org/authors/authors.php
+
+## Scope
+Journal of Stroke publishes original research, reviews, guidelines, and special reports on cerebrovascular disease, including epidemiology, risk factors, pathophysiology, diagnosis, acute treatment, secondary prevention, neurorehabilitation, and stroke systems of care. The journal prioritizes clinically translatable work and welcomes international submissions, with a strong tradition of regional stroke research from Asia.
+
+## Scope Keywords
+ischemic stroke, hemorrhagic stroke, intracerebral hemorrhage, subarachnoid hemorrhage, transient ischemic attack, acute stroke treatment, thrombolysis, mechanical thrombectomy, stroke prevention, cerebrovascular imaging, cerebral small vessel disease, stroke epidemiology, stroke outcome, neurorehabilitation, stroke guideline
+
+## Article Types Accepted
+- Special Review
+- Review
+- Original Article
+- Guideline
+- Special Report
+- Editorial
+- Letter to the Editor
+- Response to Letter
+
+## Classification
+- **Tier:** Q1
+- **Open Access:** Full OA (CC BY-NC 4.0, no APC)
+- **Field:** Stroke / cerebrovascular disease
+
+## Special Notes
+Official journal of the Korean Stroke Society, published three times per year. Full open access with no article processing charge — a rare combination for a Q1 stroke journal. Editorial Office is hosted at Asan Medical Center, Ulsan University College of Medicine. Structured abstract of 250 words required for Original Articles; references follow Vancouver numbered style. Choose Journal of Stroke over Stroke (AHA) when the target audience is regional (Asia-Pacific) or when no-APC OA is a priority. AI policy: not specified in the author guidelines (last revised 2024-01-31); default to ICMJE — disclose any AI-assisted writing in Methods or Acknowledgments.

package/skills/find-journal/references/journal_profiles/KJR.md

@@ -0,0 +1,38 @@
+# Korean Journal of Radiology
+
+## Identity
+- **Abbreviation:** Korean J Radiol
+- **Publisher:** Korean Society of Radiology
+- **ISSN:** 1229-6929 (Print) / 2005-8330 (Electronic)
+- **Homepage:** https://www.kjronline.org/
+- **Author guidelines:** https://www.kjronline.org/index.php?body=Instruction
+
+## Scope
+KJR publishes original research, reviews, and special articles across all subspecialties of diagnostic and interventional radiology. The journal explicitly excludes radiation oncology, dentistry, dental radiology, dental surgery, and translational/basic nuclear medicine studies. It has particular strength in AI/radiomics, Korean and East Asian population studies, and diseases prevalent in East Asia such as hepatocellular carcinoma, gastric cancer, and thyroid cancer.
+
+## Scope Keywords
+diagnostic radiology, AI in radiology, radiomics, deep learning, Korean radiology, hepatocellular carcinoma, thyroid imaging, gastric cancer imaging, CT, MRI, ultrasound, interventional radiology, liver imaging, breast imaging, chest imaging, structured reporting, FDA/medical-device evaluation
+
+## Article Types Accepted
+- Original Article
+- Brief Research Report
+- Review
+- Pictorial Essay
+- Focus
+- Recommendation and Guideline
+- Editorial
+- Uncover This Tech Term
+- Emerging Rad Dx
+- Letter to the Editor
+
+## Classification
+- **Tier:** Q1
+- **Open Access:** Full OA (CC BY-NC 4.0, DOAJ indexed)
+- **Field:** Radiology (general)
+
+## Special Notes
+KJR is the leading English-language radiology journal in Asia, fully open access (USD 100 APC for accepted manuscripts; invited articles, Uncover This Tech Term, Emerging Rad Dx, and Letters are exempt). Indexed in PubMed/MEDLINE, SCIE, and Scopus. Particularly receptive to AI/radiomics studies and Korean population data. Faster turnaround than Western journals (Minor Revision within 30 days; Major Revision within 60 days). References: Vancouver style with first six authors listed, then "et al." (≥7 authors). AI policy follows the journal's "Ethical and Responsible Use of Generative AI" statement (KJR 2026; https://doi.org/10.3348/kjr.2026.0166): AI cannot be author or primary scholarly source; AI use beyond routine language assistance must be disclosed in the relevant section or Acknowledgments; AI as study subject must be described in Materials and Methods; reviewers/editors must preserve confidentiality and disclose AI use beyond routine language assistance.
+
+## Verification
+- **Source:** KJR-Instructions-202603.pdf (March 2026 official author instructions)
+- **Date:** 2026-05-21

package/skills/find-journal/references/journal_profiles/Korean_Circulation_Journal.md

@@ -0,0 +1,38 @@
+# Korean Circulation Journal (KCJ)
+
+## Identity
+- **Abbreviation:** Korean Circ J
+- **Publisher:** The Korean Society of Cardiology / The Korean Cardiac Research Foundation
+- **ISSN:** 1738-5520 (print) / 1738-5555 (online)
+- **Homepage:** https://e-kcj.org/
+- **Author guidelines:** https://e-kcj.org/index.php?body=instructions
+
+## Scope
+KCJ is the official journal of the Korean Society of Cardiology, covering all aspects of cardiovascular medicine including original research of preclinical and clinical findings, state-of-the-art reviews, perspectives for outbreaking issues, editorials, images in cardiovascular medicine, and letters to the editor.
+
+## Scope Keywords
+cardiology, cardiovascular disease, Korean cohort, clinical cardiology, coronary artery disease, atherosclerosis, heart failure, arrhythmia, hypertension, preventive cardiology, cardiac imaging, Asian cardiology, KSC official journal
+
+## Article Types Accepted
+- Original Research
+- State of the Art Review
+- Perspective
+- Image in Cardiovascular Medicine
+- Letter to the Editor
+- Research Letter
+
+## Classification
+- **Tier:** Q3 (Korean society flagship)
+- **Open Access:** Open Access, peer-reviewed, monthly
+- **Field:** Cardiology — Korean Society of Cardiology flagship
+
+## Special Notes
+Editor-in-Chief In-Ho Chae, MD, PhD. Original Research capped at **5,000 words**, 8 figures/tables, with a **250-word structured abstract using Background and Objectives / Methods / Results / Conclusions**. State of the Art Reviews ≤10,000 words. Perspectives ≤2,000 words, 4 figures/tables; Research Letter ≤800 words, 1 figure/table; Letter to the Editor ≤500 words. References use **Vancouver style with numbered references in citation order**; "List all authors if 6 or fewer; otherwise, list the first 3 and add et al." Submission portal: https://kcj.edmgr.com. **AI policy is not displayed on the Instructions for Authors page** as of the audit date — refer directly to KCJ's editorial office for AI disclosure expectations. APC not specified on the guidelines page; verify at the journal's open-access policy page if Gold OA is needed. Natural home for Korean cardiovascular cohort papers that need a guaranteed publication path and KSC community visibility — best used as a safety-net target in a cascade strategy or as primary when Korean clinical-practice relevance is the dominant framing.
+
+
+---
+
+## Verification
+- **Source:** https://e-kcj.org/index.php?body=instructions
+- **Date (harvested from private profile):** 2026-05-20
+- **Date (promoted to public):** 2026-05-21

package/skills/find-journal/references/journal_profiles/Korean_Journal_of_Internal_Medicine.md

@@ -0,0 +1,36 @@
+# Korean Journal of Internal Medicine
+
+## Identity
+- **Abbreviation:** KJIM
+- **Publisher:** Korean Association of Internal Medicine
+- **ISSN:** 1226-3303 / 2005-6648
+- **Homepage:** https://www.kjim.org/
+- **Author guidelines:** https://www.kjim.org/authors/authors.php
+
+## Scope
+KJIM publishes original research, reviews, and clinical case reports across all subspecialties of internal medicine — endocrinology, gastroenterology, hematology-oncology, infectious diseases, nephrology, pulmonology, rheumatology, cardiology, geriatrics — with emphasis on Korean and East Asian clinical research.
+
+## Scope Keywords
+internal medicine, Korean cohort, East Asian medicine, endocrinology, gastroenterology, hematology, oncology, infectious disease, nephrology, pulmonology, rheumatology, cardiology, geriatrics, health screening, NHIS, clinical research, observational cohort
+
+## Article Types Accepted
+- Original Article
+- Review
+- Editorial
+- Images of Interest
+- Correspondence
+
+## Classification
+- **Tier:** Q2 (general internal medicine; verify current JCR rank)
+- **Open Access:** Full OA (CC BY-NC); APC $1,000 for Original Articles (2024-10-01)
+- **Field:** Internal medicine (general)
+
+## Special Notes
+Korean Association of Internal Medicine flagship; bimonthly publication; PubMed/PMC indexed; structured abstract requires Background/Aims, Methods, Results, Conclusions; KJIM-specific "Key Message" section is mandatory in Original Articles. Initial decision typically within 4 weeks. AI policy: mandatory AI disclosure in Acknowledgments with model name + version + source + application method; AI cannot be listed as author.
+
+
+---
+
+## Verification
+- **Source:** https://www.kjim.org/authors/authors.php
+- **Date:** 2026-05-21

package/skills/find-journal/references/journal_profiles/Lancet_Diabetes_and_Endocrinology.md

@@ -0,0 +1,40 @@
+# Lancet Diabetes & Endocrinology
+
+## Identity
+- **Abbreviation:** Lancet Diabetes Endocrinol
+- **Publisher:** Elsevier (The Lancet Group)
+- **ISSN:** 2213-8587 / 2213-8595
+- **Homepage:** https://www.thelancet.com/journals/landia/home
+- **Author guidelines:** https://www.thelancet.com/landia/information-for-authors
+
+## Scope
+Lancet Diabetes & Endocrinology publishes original research, reviews, and clinical studies in diabetes, endocrinology, and metabolism. Coverage includes type 1 and type 2 diabetes, obesity, thyroid disorders, adrenal disorders, pituitary disease, bone and mineral metabolism, reproductive endocrinology, and metabolic syndrome. The journal prioritizes large clinical trials, epidemiological studies, and translational research with global health implications.
+
+## Scope Keywords
+diabetes mellitus, type 2 diabetes, type 1 diabetes, obesity, thyroid disease, endocrinology, metabolic syndrome, insulin resistance, GLP-1 receptor agonist, HbA1c, diabetic complications, adrenal insufficiency, Cushing syndrome, osteoporosis, pituitary adenoma, PCOS, gestational diabetes
+
+## Article Types Accepted
+- Original Research (Articles)
+- Review
+- Series
+- Seminar
+- Comment
+- Correspondence
+- Clinical Picture
+- Viewpoint
+
+## Classification
+- **Tier:** Q1
+- **Impact Factor:** ~42
+- **Open Access:** Hybrid
+- **Field:** Endocrinology / Diabetes
+
+## Special Notes
+Lancet Diabetes & Endocrinology is the premier endocrinology/diabetes specialty journal within the Lancet family. Extremely competitive (acceptance rate <10%). Publishes landmark diabetes trials (e.g., SGLT2 inhibitor, GLP-1 RA outcomes). Imaging studies accepted only when part of major clinical trials (e.g., body composition imaging, pancreatic imaging in diabetes). Follows Lancet Group editorial standards: strict adherence to ICMJE, EQUATOR checklists mandatory, and preference for large multicenter international RCTs or prospective cohorts.
+
+## AI Writing Disclosure Policy
+- **Requirement level:** Required
+- **Permitted scope:** Restrictive — Lancet Group policy permits AI for language editing only; AI cannot contribute to scientific content generation; AI cannot be listed as author
+- **Disclosure location:** Acknowledgments section
+- **AI-generated images:** Not permitted for scientific content
+- **Policy URL:** https://www.thelancet.com/landia/information-for-authors

package/skills/find-journal/references/journal_profiles/Lancet_Gastroenterology_and_Hepatology.md

@@ -0,0 +1,49 @@
+# Lancet Gastroenterology & Hepatology
+
+## Identity
+- **Abbreviation:** Lancet Gastroenterol Hepatol
+- **Publisher:** Elsevier (The Lancet Group)
+- **ISSN:** 2468-1253
+- **Homepage:** https://www.thelancet.com/journals/langas/home
+- **Author guidelines:** https://www.thelancet.com/langas/information-for-authors
+
+## Scope
+The Lancet Gastroenterology & Hepatology publishes original research, reviews, comments, and clinical studies across the full spectrum of gastroenterology and hepatology. The journal favors large clinical trials, multicentre or population-scale epidemiology, evidence-synthesis (Cochrane-style and individual-patient-data meta-analyses), and translational studies with global health implications. Within hepatology it has been a primary venue for MASLD/NAFLD natural-history evidence (e.g., Hagström 2024 systematic review of natural-history rates), nomenclature debate following the 2023 multisociety Delphi statement, hepatitis B/C elimination programmes, and cirrhosis/portal-hypertension management trials.
+
+## Scope Keywords
+gastroenterology, hepatology, MASLD, NAFLD, MASH, MetALD, ALD, alcohol-associated liver disease, viral hepatitis, hepatitis B, hepatitis C, HCC, hepatocellular carcinoma, cirrhosis, portal hypertension, IBD, Crohn's disease, ulcerative colitis, irritable bowel syndrome, gastrointestinal cancer, liver transplantation, FIB-4, natural history, comparator-refinement methodology, large-cohort epidemiology, Cochrane meta-analysis
+
+## Article Types Accepted
+- Articles (Original Research; large RCTs, observational cohort, IPD meta-analysis)
+- Review
+- Series (commissioned thematic series)
+- Seminar
+- Comment (invited editorial)
+- Correspondence
+- Clinical Picture
+- Viewpoint
+- Personal View
+
+## Classification
+- **Tier:** Q1 gastroenterology and hepatology (top-tier specialty journal in Lancet group)
+- **Open Access:** Hybrid (OA optional; APC ~US$5,500 for Gold OA)
+- **Field:** gastroenterology and hepatology — clinical, epidemiological, translational
+
+## Special Notes
+**Submission guidelines are a near-verbatim shared template across the Lancet Group specialty journals (Lancet Diabetes & Endocrinology, Lancet GH, Lancet Respiratory Medicine, etc.) — same article structure, abstract, statement-of-novelty wording, AI policy, and supplementary requirements.** Beyond what the guidelines disclose, the practically relevant non-guideline factors for this venue are documented below.
+
+### Editorial culture (non-guideline)
+- **Pre-submission inquiry strongly advised.** ~60–70 % desk-reject rate for original research; pre-submission inquiry (1-page abstract + cover letter to editor@lancet.com) is the standard route to test scope fit before full submission. Decisions on inquiries typically arrive within 5–10 working days.
+- **Strong preference for "what changes practice or guideline" framing** in cover letter and Discussion. Methodology-only papers (e.g., comparator refinement as method) need an explicit "how this will change MASLD natural-history evidence appraisal worldwide" paragraph.
+- **Research in Context box mandatory at acceptance** (separate from abstract): three sub-headings (Evidence before this study / Added value of this study / Implications of all the available evidence). Drafting it pre-submission helps internal triage even though it is not officially required at initial submission.
+- **Statement of novelty / data-sharing statement mandatory** in cover letter (not in main paper). Lancet Group requires deposition pathway specified at submission, not at revision.
+
+### MASLD-natural-history precedent
+- The journal has been the de-facto reference venue for MASLD natural-history evidence since 2024 (Hagström L, et al. Clinical and prognostic outcomes after hepatocellular cancer screening, Lancet Gastroenterol Hepatol; and the post-2023 Delphi nomenclature commentaries). A Korean health-screening cohort applying the 2023 nomenclature with comparator-refinement methodology is a direct continuation of that line of evidence.
+- Reviewer pool overlaps substantially with Hepatology (AASLD), Journal of Hepatology (EASL), and Hepatology International (APASL). Suggested reviewers from these venues are typical.
+
+### Korean cohort context
+- East-Asian cohort epidemiology is regularly published, but the journal has a documented preference for *international or multi-cohort* validation (e.g., paired Korean + UK Biobank + NHANES analyses). Single-centre Korean cohorts are accepted when the methodological contribution (e.g., comparator refinement as a generalizable method) is strong enough to justify international relevance — the cover letter should pre-empt the "single-centre / Asian-only" reviewer concern.
+
+## Acceptance Rate (estimated)
+~5–8 % overall (Lancet specialty journals' published acceptance bands; ~60–70 % desk-rejected before peer review, of the remainder ~25–35 % accepted).